| Entry |
|
|---|
| Name |
Givosiran (USAN/INN) |
|---|
| Formula |
C524H694F16N173O316P43S6
|
|---|
| Exact mass |
16292.034
|
|---|
| Mol weight |
16300.3229
|
|---|
| Remark |
| Product (DG03084): | D11708<JP/US> |
|
|---|
| Efficacy |
Accumulation reduction (neurotoxic intermediates) |
|---|
| Comment |
RNA interference (RNAi) drug
Treatment of acute hepatic porphyria
|
|---|
| Target |
|
|---|
| Pathway |
| hsa00860 | Porphyrin and chlorophyll metabolism |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AX Various alimentary tract and metabolism products
A16AX16 Givosiran
D11702 Givosiran (USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Acyltransferases
ALAS1
D11702 Givosiran (USAN/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11702
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11702
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
